Concerns among some patients and healthcare providers that the recombinant zoster vaccine (RZV) could trigger autoimmune disease flares in immunocompromised patients may be unfounded, according to a large observational study.
To address the higher risk for infection with the herpes zoster virus and its complications in patients who are immunocompromised, the CDC and the Advisory Committee on Immunization Practices (ACIP) recommended a two-dose regimen of the RZV (Shingrix, GlaxoSmithKline) for